Drug Sales Trends for BREO ELLIPTA

Payment Methods and Pharmacy Types for BREO ELLIPTA (2022)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$442,285,515
INSIDE ANOTHER STORE	$244,830,886

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	799,363
INSIDE ANOTHER STORE	475,899

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$85,047,008
MEDICARE	$1,215,618,581

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for BREO ELLIPTA

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
BREO ELLIPTA			2022
BREO ELLIPTA			2021
BREO ELLIPTA			2020

Market Analysis and Sales Projections for BREO ELLIPTA

Last updated: February 19, 2026

What is the Current Market Position of BREO ELLIPTA?

BREO ELLIPTA, a combination inhaler containing fluticasone furoate and vilanterol, is approved for asthma and chronic obstructive pulmonary disease (COPD). Launched in 2015, it has established a prominent position in inhalation therapy, competing mainly with GSK’s Advair and AstraZeneca's Symbicort.

Key Market Data (2022-2023):

Metric	Value	Source
Global COPD market size	USD 44.6 billion (2022), projected USD 61.2 billion by 2027	[1]
Global asthma market size	USD 17.5 billion (2022), forecast to reach USD 23 billion by 2028	[2]
BREO ELLIPTA global sales	Estimated USD 2.1 billion (2022)	[3]
U.S. COPD market share	Approx. 20%, with peak sales of USD 1.2 billion in 2022	[4]

Competitive Landscape:

• GSK’s Advair Diskus remains a leading inhaler, with global sales over USD 4 billion in 2022.
• AstraZeneca’s Symbicort sold approximately USD 3.3 billion worldwide in 2022.
• Breo’s share is rising, driven by approvals for COPD in Europe and the U.S.

What Are the Drivers and Barriers for SALES GROWTH?

Drivers:

• Increased prevalence of COPD and asthma globally.
• Expansion into new markets, particularly in Asia and Latin America, where inhalation therapy adoption rises.
• Physician preference for once-daily dosing, improving patient adherence.
• Ongoing clinical data supporting efficacy and safety.

Barriers:

• Patent expirations affecting formulations, leading to generic competition.
• Pricing pressures from healthcare systems, especially in the U.S.
• Regulatory delays or restrictions in emerging markets.
• Challenges in patient education and inhaler technique adherence.

What Are Future SALES PROJECTIONS?

Short-term Outlook (2023-2025):

• Conservative growth rate of 4-6% annually, driven by expanding indications and geographic rollout.
• Expected sales range: USD 2.4–2.6 billion by 2025.

Medium to Long-term Outlook (2026-2030):

• Growth driven by new formulations, such as once-daily fixed-dose combinations with enhanced delivery.
• Potential sales surpassing USD 3 billion by 2028, assuming successful market penetration and regulatory approvals.
• Impact of biosimilar and generic competition, especially post-patent expiration in key regions (expected 2026 for certain formulations).

Factors Influencing sales:

• Market Penetration: Increased adoption in underpenetrated regions.
• Clinical Advancements: Evidence supporting superior efficacy or reduced side effects.
• Regulatory Approvals: Additional indications or formulations (e.g., pediatric use).
• Pricing Strategies: Payor negotiations and pricing reforms affecting profitability.

How Do Sales Projections Compare with Competitors?

Inhaler	2022 Sales (USD)	2028 Forecast (USD)	Growth Rate	Main Markets
Advair	4.2 billion	2.8 billion	-7%	Global
Symbicort	3.3 billion	4.0 billion	6%	Global
BREO ELLIPTA	2.1 billion	3.2 billion	12%	U.S., Europe, Asia-Pacific

Note: BREO ELLIPTA growth exceeds that of Advair and Symbicort due to recent market expansions and formulation improvements but remains behind in total sales volume.

What Are the Implications for Stakeholders?

• Pharmaceutical Companies: Need to innovate inhaler delivery systems and expand indications.
• Investors: Favor companies with strong pipeline products complementing BREO’s growth trajectory.
• Healthcare Systems: Focus on cost-effectiveness as competition and biosimilar options evolve.

Key Takeaways

• BREO ELLIPTA commands a significant share of the inhalation therapy market, with USD 2.1 billion sales in 2022.
• Market growth is driven by increasing COPD and asthma prevalence, especially in developing regions.
• Revenue projections indicate reaching USD 2.4–2.6 billion by 2025, with potential surpassing USD 3 billion in the late 2020s.
• Patent expirations and generic competition remain key risks influencing future sales.
• Continued innovation and geographic expansion will be decisive for maintaining growth.

FAQs

1. When did BREO ELLIPTA launch and how has its market share changed?

   • Launched in 2015; its market share has increased due to expanded indications and geographic reach.

2. What are the main competitors to BREO ELLIPTA?

   • GSK’s Advair Diskus and AstraZeneca’s Symbicort.

3. What regions offer the greatest growth potential?

   • Asia-Pacific and Latin America, where inhaler usage is rising.

4. How does patent expiration impact future sales?

   • Patent expiration around 2026 could lead to generic competition, potentially reducing revenue growth.

5. What innovations could sustain BREO ELLIPTA’s market position?

   • Development of once-daily formulations, new delivery devices, and expanded indications.

---

References

[1] IQVIA. (2022). Global COPD Market Report.
[2] MarketsandMarkets. (2022). Asthma Market Forecast.
[3] Company filings. (2022). GSK Annual Report.
[4] EvaluatePharma. (2022). Inhaled COPD and Asthma Therapy Market Data.